#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News How Does Erdosteine Perform in Combination with Antibiotics?

Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in the mucin polymer. It achieves this effect through a free thiol group in its main active metabolite, N-thiodiglycolyl-homocysteine. In addition to its mucolytic action, erdosteine exhibits antioxidant and anti-inflammatory effects and reduces bacterial adhesion, thereby enhancing the effectiveness of certain antibiotics. We provide a summary of study results demonstrating its effect on enhancing the efficacy of drugs administered in the treatment of respiratory diseases.
Source: Cough Therapy 1. 11. 2022

Journal articles Examination of circulating tumor cells in renal carcinoma

Author of the article: Petr Klézl, Jindřich Šonský, Eliška Pospíšilová, Katarína Kološtová, Vladimír Bobek, Robert Grill Source: Česká urologie | 2/2020 11. 6. 2020

News News in the Treatment of Allergic Rhinitis

According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which negatively affects the quality of daily life. Below, we summarize the new recommendations from ARIA (Allergic Rhinitis and its Impact on Asthma) from 2019 regarding the treatment of this condition and highlight a new therapeutic option offered by the fixed combination of mometasone furoate with olopatadine hydrochloride.
Source: Life Without Allergic Rhinitis 27. 4. 2022

News Efficacy and Safety of Gene Therapy Using Adeno-Associated Virus Vector in Patients with Choroideremia

Choroideremia (CHM) is a rare genetically conditioned retinal disease caused by mutations in the CHM gene, leading to a lack of production of the protein REP1 (ras-associated binding escort protein 1). Currently, there is no approved treatment for CHM. The aim of the study (Tübingen Choroideremia Gene Therapy) published last year in the journal JAMA Ophthalmology was to evaluate the safety and efficacy of subretinally applied gene therapy using an adeno-associated virus vector (AAV2), designed to deliver a functional copy of the CHM gene to patients with choroideremia.
Source: Glaucoma 27. 3. 2020

News Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol

A newly published study by authors from Singapore focused on the ability of the SEP protocol – short-term low-dose enoxaparin administration based on body weight – to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.
Source: Thromboprophylaxis 3. 1. 2024

News Is It Necessary to Discontinue Dupilumab in Patients with Atopic Dermatitis During the COVID-19 Pandemic?

Italian authors described their experiences with remote treatment of 200 atopic dermatitis (AD) patients using dupilumab during the COVID-19 pandemic outbreak in spring 2020. Observations from clinical practice, published data, and pathophysiological considerations do not suggest an increased risk of SARS-CoV-2 infection in AD patients receiving this biological treatment.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 12. 2020

News Diosmin and its application in the treatment of venous insufficiency

A number of procedures, including pharmacotherapy, are used in the treatment of chronic venous insufficiency, in which diosmin, for example, is applied. The report by pharmacologist MUDr. Jiří Slíva, Ph.D., summarizes the mechanism of action and pharmacological properties of this substance.
Source: Venous Insufficiency 27. 3. 2020

News Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?

The ideal strategy for treating rheumatoid arthritis is still the subject of research. We therefore present the results of a recent study comparing the impact of various therapeutic options when biological treatment is ineffective.
Source: Arthritis 24. 9. 2020

News Incidence of Thromboembolic Disease During Military Operations – Results of a 10-Year Review

In contemporary armed conflicts, limb injuries account for more than half of all injuries. In addition to the characteristically high incidence of infectious complications, injuries associated with military medicine also carry a high risk of thromboembolic disease. This is demonstrated by a study assessing the incidence of thromboembolic disease in American soldiers over 10 years of military operations in the Middle East.
Source: Prevention of Thrombosis in Surgery 18. 5. 2020

News ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK

Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and prevalence of HF with preserved left ventricular ejection fraction (HFpEF) rising. The following document focuses on individuals with HFpEF and supports the principles of evidence-based diagnosis and treatment of HF from 2022. It emphasizes the need for individualized care and multidisciplinary cooperation.
Source: Heart Failure 14. 3. 2024

News Lurasidone in Antipsychotic Therapy – A Case Study of a Virtual Patient from the Laurie Project

MUDr. Elis Bartečků, Ph.D., from the Department of Psychiatry at MU LF and FN Brno presented the current possibilities of telemedical education at the XIV congress of the Psychiatric Society of the CLS JEP in Mikulov, specifically the so-called virtual patient within the interactive online Laurie project by Angelini Pharma. The presentation involved the case of a 20-year-old man with a severe psychotic disorder and equally severe somatic comorbidity.
Source: Modern Treatment of Schizophrenia 18. 8. 2022

News To what extent can improvement of nutritional status through parenteral nutrition affect the results of oncological treatment?

Just like cancer patients and their caregivers, doctors often overlook the risk of malnutrition. Good nutrition can be a predictor of survival in patients with malignancies.
Source: Parenteral Nutrition 14. 11. 2022

News INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension.
Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment

Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is usually associated with the early development of chronic obstructive pulmonary disease (COPD) or liver damage. We discuss how modern substitution therapy can change patients' prognosis and when to consider this diagnosis with the head of the Clinic of Pulmonary Diseases and Tuberculosis at Masaryk University Faculty of Medicine and Brno University Hospital, Doc. MUDr. Milan Sova, Ph.D.
Source: Deficiency of Alpha-1-Antitrypsin 18. 1. 2024

News Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy – Current Clinical Practice Data

If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined maintenance therapy, dupilumab – a recombinant monoclonal antibody inhibiting the signaling pathway of interleukins 4 and 13 – can be added. What is its efficacy in clinical practice? We summarize findings from 3 recent retrospective studies.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 16. 3. 2023

News Metamizole, even after 100 years on the market, remains an important component of postoperative pain therapy

Metamizole has been used in the therapy of a wide range of acute and chronic pains for 100 years. Thanks to a number of advantages, it still represents one of the most frequently used analgesics in daily clinical practice.
Source: Analgesia 28. 2. 2022

News Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL

Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL), showing higher efficacy and safety compared to standard chemoimmunotherapy. Until recently, an important question remained unanswered: whether the administration of Bruton tyrosine kinase inhibitors (BTKi) after previous therapy with the BCL-2 inhibitor venetoclax provides sufficient clinical effect.
Source: Chronic Lymphocytic Leukemia 11. 12. 2020

News What affects the elimination of bisoprolol in diabetics and patients with acute coronary syndrome?

Beta-blockers are widely used to reduce cardiovascular (CV) risk in a number of diseases. However, information about the pharmacokinetics of these drugs is still far from complete. Two studies focused on the population pharmacokinetics (PopPK) of bisoprolol in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD), and we summarize their conclusions.
Source: Cardiovascular Continuum 16. 9. 2022

News Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria

Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy with the combination of ceftazidime/avibactam (a third-generation cephalosporin and a beta-lactamase inhibitor) in treating these infections compared to the 'best available antibiotic therapy' (BAT).
Source: Anti-Infectives 22. 8. 2023

News Overall Survival and Tolerance of Olaparib in the OlympiAD Study – Results of Extended Follow-up

Olaparib provides women with metastatic breast cancer with a germline BRCA mutation, who have not been pre-treated with chemotherapy, not only with extended progression-free survival but also, according to the latest reports, longer overall survival. Its tolerability is good over the long term.
Source: Ovarian and Breast Cancer 28. 5. 2020

News Metamizole in the Treatment of Acute Postoperative Pain

In many countries, metamizole is considered a first-choice non-opioid analgesic. The analysis presented below, published in the Cochrane Database of Systematic Reviews, examined the efficacy and safety of metamizole in the treatment of acute postoperative pain.
Source: Analgesia 25. 5. 2021

News Interchangeability of Diosmin and Micronized Purified Flavonoid Fraction

Among the medicinal products reimbursed for chronic venous disease, those containing micronized diosmin (Diozen 180 tbl.) have been newly included. Which substances are available for this indication, and what determined the interchangeability of micronized diosmin with micronized purified flavonoid fraction (MPFF) and other selected venotonics stabilizing capillaries?
Source: Venous Insufficiency 16. 9. 2022

News RETRO-TAS Study – Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice

How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.
Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?

What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of treating ankylosing spondylitis (AS) with the Janus kinase inhibitor (JAKi) tofacitinib? The authors of the cited study below sought to answer this question, with their results presented at this year’s annual EULAR congress, which took place in Milan, Italy, at the traditional turn of May and June.
Source: Arthritis 22. 8. 2023

News How Does Memantine Currently Stand in Alzheimer's Disease and Other Dementias

A comprehensive meta-analysis from 2019 examined the effect and safety of administering memantine, particularly in patients with moderate to severe Alzheimer's disease. How did memantine fare?
Source: Cognitive in the treatment of Alzheimer's disease 17. 10. 2021

1 26 27 28 29 30 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#